-
1
INFLUENCE OF IMMUNOSUPPRESSIVE AND GENETICALLY ENGINEERED THERAPY WITH TNF –alpha INHIBITOR INFLIXIMAB ON MINERAL DENSITY OF BONE TISSUE IN PATIENTS WITH JUVENILE ARTHRITIS
Published 2010-07-01“…Administration of immunosuppressants is unfavorable factor of osteoporosis development in all types of juvenile arthritis. …”
Get full text
Article -
2
INFLUENCE OF IMMUNOSUPPRESSIVE AND GENETICALLY ENGINEERED THERAPY WITH TNF –alpha INHIBITOR INFLIXIMAB ON MINERAL DENSITY OF BONE TISSUE IN PATIENTS WITH JUVENILE ARTHRITIS
Published 2010-01-01“…Administration of immunosuppressants is unfavorable factor of osteoporosis development in all types of juvenile arthritis. …”
Get full text
Article -
3
EFFECTIVENESS AND SAFETY OF RECOMBINANT HUMAN GRANULOCYTIC COLONY-STIMULATING FACTOR IN TREATMENT OF GRANULOCYTOPENIA DEVELOPED DURING IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS
Published 2010-01-01“…During the last years genetically engineered biological drugs are used equally with traditional immunosuppressive agents in treatment of severe forms of juvenile arthritis. …”
Get full text
Article -
4
EFFECTIVENESS AND SAFETY OF RECOMBINANT HUMAN GRANULOCYTIC COLONY-STIMULATING FACTOR IN TREATMENT OF GRANULOCYTOPENIA DEVELOPED DURING IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS
Published 2010-07-01“…During the last years genetically engineered biological drugs are used equally with traditional immunosuppressive agents in treatment of severe forms of juvenile arthritis. …”
Get full text
Article -
5
EFFICACY OF RECURRENT TREATMENT WITH RITUXIMAB IN PATIENT WITH SEVERE REFRACTORY SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS
Published 2009-11-01“…The article presents a case report of severe clinical course of systemic type of juvenile rheumatoid arthritis refractory to the immunosuppressive treatment. The disease was characterized with such extra-articular symptoms as fever, lymphadenopathia, hepatosplenomegaly, polyserositis. …”
Get full text
Article -
6
PRACTICE OF INFLIXIMAB TREATMENT OF A PATIENT WITH SEVERE POLIARTICULAR JUVENILE RHEUMATOID ARTHRITIS
Published 2011-09-01“…This article contains observation of severe poliarticular variant of juvenile rheumatoid arthritis, resistant to glucocorticoid treatment and classic immunosuppressive therapy. There is a description of biologic treatment — with chimeriс antibodies to TNF α — infliximab in a patient with protracted aggressive arthritis (duration of the disease more than 5 years). …”
Get full text
Article -
7
EFFICACY OF RECURRENT TREATMENT WITH RITUXIMAB IN PATIENT WITH SEVERE REFRACTORY SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS
Published 2009-01-01“…<em>The article presents a case report of severe clinical course of systemic type of juvenile rheumatoid arthritis refractory to the immunosuppressive treatment. The disease was characterized with such extra-articular symptoms as fever, lymphadenopathia, hepatosplenomegaly, polyserositis. …”
Get full text
Article -
8
PRACTICE OF INFLIXIMAB TREATMENT OF A PATIENT WITH SEVERE POLIARTICULAR JUVENILE RHEUMATOID ARTHRITIS
Published 2011-01-01“…<em>This article contains observation of severe poliarticular variant of juvenile rheumatoid arthritis, resistant to glucocorticoid treatment and classic immunosuppressive therapy. There is a description of biologic treatment — with chimeriс antibodies to TNF α — infliximab in a patient with protracted aggressive arthritis (duration of the disease more than 5 years). …”
Get full text
Article -
9
QUALITY OF LIFE IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS IN THE CONDITIONS OF TREATMENT WITH CHIMERIC MONOCLONAL ANTIBODIES TO TNF α
Published 2009-05-01“…The article presents results of study of inhibitor TNF α — infliximab — on quality of life in patients with juvenile arthritis, refractory to standard immunosuppressive treatment. In 1.5 months after the beginning of treatment, the quality of life increased in 98% of patients; and in one year, the rates of physical functioning were similar to it in healthy children the same age.Key words: children, juvenile arthritis, quality of life, infliximab.…”
Get full text
Article -
10
ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
Published 2009-05-01“…This article presents the results of a trial, studying effectiveness and safety of adalimumab in treatment of 16 patients with different types of juvenile arthritis, refractory to standard immunosuppressive treatment and infliximab. The treatment with adalimumab provided the development of articular syndrome and uveitis remission, decreasing and normalization of laboratory indices of disease activity, lessening of disabling disorders rate, increase of quality of life in all patients. …”
Get full text
Article -
11
TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Published 2011-05-01“…This article contains results of the research of tocilizumab treatment efficacy and safety in 39 patients with severe systemic juvenile idiopathic arthritis, resistant to standard immunosuppressive treatment. Tocilizumab efficacy analysis has shown 50% of patients with inactive disease after 6 months of treatment, and 57% of patients with inactive disease after 12 months. …”
Get full text
Article -
12
EXPERIENCE OF CLINICAL USE OF RITUXIMAB IN PATIENT WITH SYSTEMIC JUVENILE ARTHRITIS (A CASE REPORT)
Published 2008-06-01“…The case of early onset and severe course of systemic juvenile rheumatoid arthritis refractory to classic immunosuppressive agents and blockers of tumor necrosis factor (TNF) is presented in this article. …”
Get full text
Article -
13
EFFICACY OF ETANERCEPT IN CHILD WITH SEVERE POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITIS
Published 2011-03-01“…The article presents a case report of severe and prolonged polyarticular rheumatoid arthritis resistant to the treatment with classic immunosuppressive agents, nonsteroidal anti-inflammatory drugs and corticosteroids. …”
Get full text
Article -
14
EXPERIENCE OF CLINICAL USE OF RITUXIMAB IN PATIENT WITH SYSTEMIC JUVENILE ARTHRITIS (A CASE REPORT)
Published 2008-01-01“…<em>The case of early onset and severe course of systemic juvenile rheumatoid arthritis refractory to classic immunosuppressive agents and blockers of tumor necrosis factor (TNF) is presented in this article. …”
Get full text
Article -
15
RESULTS OF RETROSPECTIVE OBSERVATIONAL STUDY OF ADALIMUMAB SAFETY AND EFFICACY IN PATIENTS WITH JUVENILE ARTHRITIS AND UVEITIS
Published 2011-11-01“…The article contains results of retrospective observational study of adalimumab safety and efficacy in 67 juvenile arthritis and juvenile arthritis with eye involvement patients refractory to classical immunosuppressive treatment. It also contains a description of a recombinant biological medication — adalimumab: already on the 4th week of treatment acute inflammatory changes in the affected joints were relieved, joint motion range fully recovered; by the week 8 — full remission of the uveitis was reported in 45% of affected eyes (27/61), normalized disease activity lab parameters such as ESR, serum C-reactive protein.Key words: children, juvenile rheumatoid arthritis, rheumatoid uveitis, adalimumab. …”
Get full text
Article -
16
QUALITY OF LIFE IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS IN THE CONDITIONS OF TREATMENT WITH CHIMERIC MONOCLONAL ANTIBODIES TO TNF α
Published 2009-01-01“…<strong></strong><em>The article presents results of study of inhibitor TNF<span class="st"> α</span> — infliximab — on quality of life in patients with juvenile arthritis, refractory to standard immunosuppressive treatment. In 1.5 months after the beginning of treatment, the quality of life increased in 98% of patients; and in one year, the rates of physical functioning were similar to it in healthy children the same age.…”
Get full text
Article -
17
NEW OPPORTUNITIES IN TREATMENT OF SEVERE SYSTEMIC TYPE OF JUVENILE ARTHRITIS
Published 2010-07-01“…The article presents a case report of a severe clinical course of systemic type of juvenile arthritis, resistant to treatment with corticosteroids and classic immunosuppressive agents in girl 9 years old. Biological agent — tocilizumab showed beneficial effect: exudative lesions of joints, morning joint stiffness stopped and the range of motions restored in almost all affected joints in 8 weeks of treatment. …”
Get full text
Article -
18
EXPERIENCE OF ADMINISTRATION OF SOLUBLE RECEPTORS TO TNF-α IN PATIENT WITH SEVERE POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITIS
Published 2010-05-01“…The article presents a case report of early debut and severe clinical course of polyarticular type of juvenile rheumatoid arthritis which was refractory to the treatment with classical immunosuppressants and secondary inefficiency of chimeruc monoclonal antibodies to tumor necrotizing factor (TNF). …”
Get full text
Article -
19
ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
Published 2009-01-01“…<em>This article presents the results of a trial, studying effectiveness and safety of adalimumab in treatment of 16 patients with different types of juvenile arthritis, refractory to standard immunosuppressive treatment and infliximab. The treatment with adalimumab provided the development of articular syndrome and uveitis remission, decreasing and normalization of laboratory indices of disease activity, lessening of disabling disorders rate, increase of quality of life in all patients. …”
Get full text
Article -
20
EFFICACY OF ETANERCEPT IN CHILD WITH SEVERE POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITIS
Published 2011-01-01“…<em>The article presents a case report of severe and prolonged polyarticular rheumatoid arthritis resistant to the treatment with classic immunosuppressive agents, nonsteroidal anti-inflammatory drugs and corticosteroids. …”
Get full text
Article